Focused on making an impact in the lives of people living with cancer
Cyclacel’s pipeline of medicines aims to provide safe and effective anticancer treatment options to patients combined with the convenience of oral administration. We have retained worldwide rights for all of our prescription candidates, excluding in Japan for sapacitabine.
Our Clinical Trials
Fadraciclib is a highly selective inhibitor of CDK2 and CDK9 currently being evaluated in midstage clinical trials in both patients with solid cancers and hematologic malignancies.
Sapacitabine (CYC682) is an orally available nucleoside analogue with a unique DDR mechanism.
Cyclacel’s candidates are experimental drugs under clinical investigation. They are not approved for human use at this time.